PD173074

For research use only. Not for use in humans.

Pfizer辉瑞授权目录号：S1264

CAS No. 219580-11-7

PD173074 是一种有效的FGFR1抑制剂，在无细胞试验中IC50约为25 nM，也能抑制VEGFR2，IC50为100-200 nM，作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。PD173074 可在胃癌细胞中抑制增殖并促进凋亡。

规格

价格

库存

购买数量

5mg	RMB 575.36	现货
10mg	RMB 985.04	现货
50mg	RMB 3867.14	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PD173074发表文献81篇：

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Genet, 2015, 47(9):1003-10

PubMed: 26258846 ( click the link to review the publication )

Nat Methods, 2014, 11(8):855-60

PubMed: 24930130 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

J Exp Med, 2020, 3;217(8):e20191805

PubMed: 32434218 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Front Pharmacol, 2020, 11:154

PubMed: 32184729 ( click the link to review the publication )

Neuroscience, 2020, 1;436:1-10

PubMed: 32278061 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32024006 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Stem Cell Res, 2020, 48:101951

PubMed: 32798915 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30720426 ( click the link to review the publication )

Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30866584 ( click the link to review the publication )
Exp Neurol, 2019, 317:34-50

PubMed: 30802446 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0256-3

PubMed: 31028279 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

ACS Comb Sci, 2019, 21(12):805-816

PubMed: 31689077 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(1):151-160

PubMed: 29763898 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Cells, 2018, 7(12)

PubMed: 30544798 ( click the link to review the publication )

J Cell Sci, 2018, 131(18)

PubMed: 30154213 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1389-1398

PubMed: 30123084 ( click the link to review the publication )

Front Neurosci, 2018, 12:582

PubMed: 30210273 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(1):76-86

PubMed: 29257923 ( click the link to review the publication )

Dev Biol, 2018, 433(2):394-403

PubMed: 29291983 ( click the link to review the publication )

Biomed Pharmacother, 2018, 103:1516-1525

PubMed: 29864937 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )

PLoS One, 2017, 12(2):e0171898

PubMed: 28207787 ( click the link to review the publication )

J Orthop Sci, 2017, 22(6):1112-1119

PubMed: 28877850 ( click the link to review the publication )
Oncotarget, 2017, 8(54):91841-91859

PubMed: 29190880 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(1):84-94

PubMed: 28076758 ( click the link to review the publication )

Nat Commun, 2016, 7:13796

PubMed: 27982029 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )

Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

Cell Oncol (Dordr), 2016, 39(3):229-42

PubMed: 26883759 ( click the link to review the publication )

Dev Biol, 2016, 415(2):228-241

PubMed: 26988119 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):32-40

PubMed: 25344834 ( click the link to review the publication )

Cancer Sci, 2015, 106(10):1278-87

PubMed: 26183471 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(8):644-55

PubMed: 25220592 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 23):5079-92

PubMed: 25278553 ( click the link to review the publication )
J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )

Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述

靶点

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

体外研究

PD173074是FGFR1的ATP竞争性抑制剂， K_i约为40 nM。PD173074也是VEGFR2的有效抑制剂。相比FGFR1，PD173074弱抑制Src，INSR，EGFR，PDGFR，MEK和PKC的活性，IC 50值大1000倍以上。PD173074剂量依赖性地抑制FGFR1和VEGFR2的自身磷酸化，IC50 分别为1-5 nM和100-200 nM。^[1] PD173074以剂量依赖的方式抑制FGF-2促进的颗粒神经元存活，IC50是12 nM，活性是SU 5402的1,000倍以上。^[2] D173074特异性地抑制FGF-2-介导的少突胶质细胞（OL）谱系细胞的细胞增殖，分化和MAPK激活。^[3] 在多发性骨髓瘤（MM）细胞系中，PD173074对野生受体和FGFR3突变有活性。PD173074还以剂量依赖的方式有效地抑制FGFR3的自磷酸化，IC50约为5 nM。PD173074有力地降低了表达FGFR3的KMS11细胞和KMS18细胞的活力，IC50小于20 nM。aFGF刺激的MM细胞生长受PD173074抑制是和FGFR3的表达高度相关的。PD173074完全抑制由Y373C FGFR3介导而不是的Ras介导的NIH 3T3转化，这表明PD173074专门针对FGFR3基因介导的细胞转化和缺乏非特异性的细胞毒性作用。PD173074也诱导KMS11和KMS18细胞功能成熟。^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1581	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\tdHFSUUN3ME2wMlAyOjJ3IN88US=>	NFTwSplUSU6JRWK=
KG-1	M2TDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\xcWlEPTB;MD6wOVEzQSEQvF2=	NIjOOGZUSU6JRWK=
MFM-223	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nWZmlEPTB;MD6yNVU4PiEQvF2=	NXS1eZFzW0GQR1XS
EoL-1-cell	NUHFXIJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7HNpdKSzVyPUCuN\|I6QDRizszN	MYTTRW5ITVJ?
ECC10	NWXwR5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj5emF{UUN3ME2wMlM{QDl6IN88US=>	NUTyRVVzW0GQR1XS
H-EMC-SS	M2DCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jkRWlEPTB;MD6zOFcyPSEQvF2=	NGn6eWdUSU6JRWK=
AN3-CA	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP1VGhKSzVyPUCuOFAyOzNizszN	M2LjPHNCVkeHUh?=
HuO-3N1	NEfaOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwNUS2OVMh\|ryP	NILsdHpUSU6JRWK=
RT-112	NEHYOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonoTWM2OD1yLkW0O\|AyKM7:TR?=	MWnTRW5ITVJ?
NEC8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwNU[yPFkh\|ryP	NX60cYI2W0GQR1XS
D-263MG	NV7xXIZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoWwTWM2OD1yLkexNVU6KM7:TR?=	NF;HdnZUSU6JRWK=
SW962	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwN{i5PFgh\|ryP	NX3vWIw6W0GQR1XS
BV-173	NGjYWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NISwWoZKSzVyPUCuPFQ3OjNizszN	NEXEfG9USU6JRWK=
MFE-280	M17NdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHXS2RGUUN3ME2wMlg2QDd{IN88US=>	MojaV2FPT0WU
HuH-7	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXQcoNCUUN3ME2xMlI1PDZ2IN88US=>	NFW4W25USU6JRWK=
RS4-11	M{XWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu4TWM2OD1zLkOzPFg3KM7:TR?=	MWrTRW5ITVJ?
DMS-114	NVHwTnppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPHUYVnUUN3ME2xMlM3PzN5IN88US=>	MoTDV2FPT0WU
MSTO-211H	M2C2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nBNWlEPTB;MT60O\|M4QCEQvF2=	NI\UbIlUSU6JRWK=
DU-145	NVfWc5dzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTFwNUiyNVch\|ryP	NUP4U5F{W0GQR1XS
A172	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfvTWM2OD1zLkewN\|U2KM7:TR?=	Mk\SV2FPT0WU
SBC-1	M{HZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELSSJNKSzVyPUKuNFk1KM7:TR?=	MWXTRW5ITVJ?
H9	NEWxZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjQTWM2OD1{LkG0N\|A3KM7:TR?=	NUfIcZB5W0GQR1XS
NCI-SNU-1	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHZOZRKSzVyPUKuNVg{QTRizszN	MUDTRW5ITVJ?
NCI-H720	NH3H[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTJwMkGyPFMh\|ryP	MWfTRW5ITVJ?
HCC2218	NWXXUWdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIe3PYtKSzVyPUKuN\|c6OzlizszN	M2\nUnNCVkeHUh?=
G-401	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTEbWRKUUN3ME2yMlQ4OTh7IN88US=>	M2XaVXNCVkeHUh?=
MPP-89	NX;5eHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTJwNEizOlQh\|ryP	NVfjVGR{W0GQR1XS
697	NGf5OnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFThNJFKSzVyPUKuOlU{OzFizszN	M3zLdHNCVkeHUh?=
KARPAS-45	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTJwN{C3OFch\|ryP	NWfrN2ZoW0GQR1XS
MG-63	NF3Ne3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJwOUSyOlIh\|ryP	NFe4OGJUSU6JRWK=
NTERA-S-cl-D1	NV\yXGVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTNwMEO0O\|Ih\|ryP	NFfVfZlUSU6JRWK=
G-402	NFLt[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[4TWM2OD1\|LkGyO\|I4KM7:TR?=	M1;NdXNCVkeHUh?=
NKM-1	NYnSW2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLEXnZNUUN3ME2zMlE{PTZ2IN88US=>	NYjofZVSW0GQR1XS
RH-18	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTNwMUm1PVgh\|ryP	NFnPbXRUSU6JRWK=
NCI-H1092	M{D3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nYeWlEPTB;Mz6xPVY6KM7:TR?=	NX;2bpBkW0GQR1XS
RPMI-8226	NVLFRZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULnU4psUUN3ME2zMlI{PDR5IN88US=>	MX\TRW5ITVJ?
GAMG	NFO5THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPYU\|BKSzVyPUOuOFY2PzZizszN	MYfTRW5ITVJ?
HH	M1TjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHBbpBTUUN3ME2zMlQ4Pjd4IN88US=>	MV;TRW5ITVJ?
RO82-W-1	NYDFRXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\NeFhKSzVyPUOuOFk5PTVizszN	MXPTRW5ITVJ?
CCRF-CEM	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL3V3hTUUN3ME2zMlUxPDh6IN88US=>	MUjTRW5ITVJ?
NBsusSR	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHoUm0xUUN3ME2zMlY{QTZ7IN88US=>	NGG4eHNUSU6JRWK=
CHL-1	NWXYSoVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7YWGJKUUN3ME2zMlY2Pzl7IN88US=>	MkDRV2FPT0WU
LK-2	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjLTWM2OD1\|Lk[3NVM{KM7:TR?=	NHv5N2VUSU6JRWK=
Hs-578-T	MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DnNmlEPTB;Mz62O\|g4OyEQvF2=	NITHXGxUSU6JRWK=
CTB-1	M3nMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfl[5VSUUN3ME2zMlgxODVzIN88US=>	MYfTRW5ITVJ?
ES5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTNwOEO2N\|ch\|ryP	NXPzcI1TW0GQR1XS
A204	NVTkR4R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDWSVdsUUN3ME2zMlkzODd3IN88US=>	M2rDNnNCVkeHUh?=
SW780	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDae2d2UUN3ME2zMlkzOjR3IN88US=>	MmLJV2FPT0WU
EW-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;VNoVKSzVyPUOuPVg6OjNizszN	NHHYVHBUSU6JRWK=
A704	NXzRVmNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPoeHZKSzVyPUSuNlg4OjNizszN	MmPHV2FPT0WU
LU-139	M2GxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;xPY5KSzVyPUSuN\|E2OzRizszN	MnzGV2FPT0WU
CAL-72	M2rmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[w[2NKSzVyPUSuOFE4PDZizszN	NHO5cVJUSU6JRWK=
D-336MG	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XZcGlEPTB;ND60OlgyPyEQvF2=	NILPO5ZUSU6JRWK=
LAMA-84	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTRwNUOzNUDPxE1?	NGLOdoRUSU6JRWK=
GI-ME-N	NFTUenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTHTWM2OD12LkW0PFEh\|ryP	NFrDZlBUSU6JRWK=
KM-H2	M3PldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;rPHYyUUN3ME20MlU2OjJ{IN88US=>	MVPTRW5ITVJ?
NCI-H209	NF7qdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HQO2lEPTB;ND61PFI5OyEQvF2=	NF2yVphUSU6JRWK=
IGROV-1	NYTiSXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fUeWlEPTB;ND64O\|E3QCEQvF2=	NEHqcWlUSU6JRWK=
L-363	NEXtd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjwTWM2OD12Lkm2OlY2KM7:TR?=	NH34fm1USU6JRWK=
SK-MEL-3	M3[2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDqVXNKSzVyPUWuNlQxPiEQvF2=	NVnDTpd2W0GQR1XS
HuO9	M1jQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjUTWM2OD13LkO4PFQ{KM7:TR?=	NGfad5FUSU6JRWK=
NOS-1	NH;5cVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXa[HdTUUN3ME21MlczQTJ5IN88US=>	Mlq5V2FPT0WU
NCI-H1770	MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPwXJBQUUN3ME21Mlk2ODN{IN88US=>	M1\TR3NCVkeHUh?=
SF126	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DiTmlEPTB;Nj6yNVQxPiEQvF2=	M4nWXHNCVkeHUh?=
ML-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D1emlEPTB;Nj6yOFk4PyEQvF2=	M2LSXnNCVkeHUh?=
CHP-134	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT5do9jUUN3ME22MlI2OTh{IN88US=>	MoTEV2FPT0WU
NCI-H1355	NVe2[WpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrqdWh3UUN3ME22MlQyPzN\|IN88US=>	MWLTRW5ITVJ?
TE-12	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TzTGlEPTB;Nj63NlY4OSEQvF2=	MmnRV2FPT0WU
A4-Fuk	NV3POHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXRSlJGUUN3ME22Mlc{OTR{IN88US=>	NWXDN4lpW0GQR1XS
MV-4-11	NYGzSmRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7iTWM2OD14Lke2OlI3KM7:TR?=	M3HuU3NCVkeHUh?=
SK-UT-1	M{DhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LXNWlEPTB;Nj65NVc5PCEQvF2=	M3jSfHNCVkeHUh?=
J-RT3-T3-5	M3L4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPGTWM2OD15LkC3O\|Y1KM7:TR?=	M3nYeHNCVkeHUh?=
ME-180	M1zEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlezTWM2OD15LkGwOFA1KM7:TR?=	NWnpbpdOW0GQR1XS
SK-MEL-28	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojVTWM2OD15LkO3PFE6KM7:TR?=	NFTiXWhUSU6JRWK=
HAL-01	NE\zVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvzTWM2OD15LkS4N\|QyKM7:TR?=	M2XmOXNCVkeHUh?=
ES8	M3yxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3RSlBKSzVyPUeuOlk3OjZizszN	NF;C[ndUSU6JRWK=
DB	M2W3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TaTGlEPTB;OD6xNVUxPCEQvF2=	MkXqV2FPT0WU
SK-NEP-1	NYC2bVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRThwNEixOFkh\|ryP	MoPiV2FPT0WU
COR-L88	M1vJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\kV2lEPTB;OD61NFk5OSEQvF2=	NVXI[\|Q{W0GQR1XS
LB1047-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml63TWM2OD16LkWyNlEzKM7:TR?=	NVy0Zmp1W0GQR1XS
NCI-H520	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP4c\|M4UUN3ME24MlYzOTV5IN88US=>	MoDLV2FPT0WU
SW954	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7OXIF6UUN3ME24MlY6Pzh4IN88US=>	M{DsXnNCVkeHUh?=
TE-6	NYTtS5czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{n1fmlEPTB;OD63OVE1OyEQvF2=	M4[xOHNCVkeHUh?=
D-283MED	M1rHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTMTWM2OD17LkC2OVM1KM7:TR?=	M4ryc3NCVkeHUh?=
DBTRG-05MG	NYnvPXlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTlwMEm2NFch\|ryP	NVfjNm1PW0GQR1XS
NCI-H446	NV:0eIJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fvT2lEPTB;OT6yPVUzPiEQvF2=	MkDTV2FPT0WU
HOS	NFi5WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW5ZpVKSzVyPUmuN\|UyOzRizszN	NWfp[\|JpW0GQR1XS
ES4	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PJTmlEPTB;OT61NFU6PSEQvF2=	M1[x[3NCVkeHUh?=
EW-13	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT4R21KSzVyPUmuPFkxPTVizszN	MYjTRW5ITVJ?
IST-MES1	M3jwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3UTWM2OD17Lkm0OVM1KM7:TR?=	MUHTRW5ITVJ?
CAS-1	NX6yc5ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHRdoZKSzVyPUmuPVc3PTlizszN	M4TqOHNCVkeHUh?=
EM-2	M3nDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjIVIhKSzVyPUGwMlE{QTNizszN	MV;TRW5ITVJ?
SW948	NHfxWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXPbGNGUUN3ME2xNE4yQDh{IN88US=>	M{O5cnNCVkeHUh?=
OAW-42	NIrLR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W2VWlEPTB;MUCuOVI3PyEQvF2=	MVPTRW5ITVJ?
BE-13	M3;Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2L4VmlEPTB;MUCuOlU4PiEQvF2=	NVv0UZlGW0GQR1XS
KU812	M1W2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUO5ZZRbUUN3ME2xNE44OzlzIN88US=>	NHTNbWhUSU6JRWK=
SK-MEL-30	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFyLki5NFEh\|ryP	M2TJT3NCVkeHUh?=
A2780	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLmOoY2UUN3ME2xNU4xOzB6IN88US=>	NUTSdIlLW0GQR1XS
TGBC24TKB	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHKcHZKSzVyPUGxMlA4OzdizszN	MYDTRW5ITVJ?
GOTO	M4G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPVVIRKSzVyPUGxMlIxQDRizszN	MXfTRW5ITVJ?
NCI-H526	NF;QUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTFzLkO4N\|ch\|ryP	MkCxV2FPT0WU
BHT-101	NGXKeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIG3NGdKSzVyPUGxMlQ1PTZizszN	Mnu2V2FPT0WU
NCI-H1155	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonVTWM2OD1zMT60PVQ4KM7:TR?=	MYXTRW5ITVJ?
MCF7	NHXTVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTFzLk[xOlch\|ryP	M{LBZnNCVkeHUh?=
MKN45	NFPVT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moq0TWM2OD1zMT63PVk{KM7:TR?=	MWrTRW5ITVJ?
MOLT-16	Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PLPWlEPTB;MUGuPVY6OiEQvF2=	NYL2UZlKW0GQR1XS
YH-13	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjtRlNKSzVyPUGyMlA{PDZizszN	M{TmPHNCVkeHUh?=
P12-ICHIKAWA	NGG1bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHyTpN6UUN3ME2xNk4{QDR3IN88US=>	MWrTRW5ITVJ?
GR-ST	M4XGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzU[nB6UUN3ME2xNk42Ojl3IN88US=>	NWDsPGdHW0GQR1XS
CAKI-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoCwTWM2OD1zMj63PVEh\|ryP	M{\aXXNCVkeHUh?=
LXF-289	NEHteVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmGwTWM2OD1zMz6wPFM2KM7:TR?=	MkixV2FPT0WU
MHH-PREB-1	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPJcmxqUUN3ME2xN{4zPzB2IN88US=>	M37iPXNCVkeHUh?=
EW-16	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTxTWM2OD1zMz6zNVg4KM7:TR?=	M3XUV3NCVkeHUh?=
NCI-H82	NUTrdHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTF\|LkSxPVUh\|ryP	Mlm1V2FPT0WU
MMAC-SF	NHO0VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjWN21KSzVyPUGzMlQ2PDdizszN	MV3TRW5ITVJ?
COLO-684	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PTXGlEPTB;MUOuOVMyQCEQvF2=	NHv4fWNUSU6JRWK=
QIMR-WIL	NXPTVGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF\|LkixNFkh\|ryP	NXfEZXg2W0GQR1XS
NB69	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHQSnY1UUN3ME2xN{46QDZ6IN88US=>	NXzQbXp2W0GQR1XS
NCI-H2291	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTF2LkS0OVMh\|ryP	MlHXV2FPT0WU
MKN7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzGOJFKSzVyPUG0MlY3PzZizszN	M1\HcHNCVkeHUh?=
HDLM-2	M{PzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTrNlgzUUN3ME2xOU4yOjh4IN88US=>	MX7TRW5ITVJ?
A253	M1TrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLjTWM2OD1zNT6zPFY6KM7:TR?=	MV3TRW5ITVJ?
SK-LU-1	M3X5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWm1T2RvUUN3ME2xOU46ODl2IN88US=>	M1y2[3NCVkeHUh?=
MEG-01	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\TcFZKSzVyPUG1MlkyODdizszN	M4HXdnNCVkeHUh?=
SK-N-DZ	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XPTmlEPTB;MUWuPVM4PiEQvF2=	Mn3tV2FPT0WU
H4	M1W3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7ORZJuUUN3ME2xOk4xQDhizszN	MWTTRW5ITVJ?
LU-65	M1HnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\VemJKSzVyPUG2MlM{QDRizszN	MXrTRW5ITVJ?
NCI-H1048	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDleHdKSzVyPUG2MlUyPjVizszN	NXnM[XZZW0GQR1XS
LCLC-97TM1	NGrpTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHCb2xKSzVyPUG2MlU5QDlizszN	NWHGd5ZNW0GQR1XS
CAL-120	M2rk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFGwRpRKSzVyPUG2Mlk5PzlizszN	MU\TRW5ITVJ?
LU-134-A	NF76ZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF5LkOzPVEh\|ryP	NYXRUo5RW0GQR1XS
SK-MEL-1	NFraNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjkRpZKSzVyPUG3MlcyOjdizszN	NXT1ZYhUW0GQR1XS
NCI-H69	NEjyWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXT4dmN7UUN3ME2xO{46OzB5IN88US=>	M370OXNCVkeHUh?=
MC116	NVm1Z5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\4cVRvUUN3ME2xO{46PzVizszN	NFXVUGxUSU6JRWK=
UMC-11	M3j6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXyTWM2OD1zOD6xO\|g5KM7:TR?=	NVnFN2toW0GQR1XS
HCC1395	M{nvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTF6LkSzNFEh\|ryP	NFf3TpdUSU6JRWK=
no-10	NX\QPGpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXW5SnhxUUN3ME2xPE43Ozh6IN88US=>	MlW0V2FPT0WU
NY	NIXJd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPRTWM2OD1zOT6wPFA6KM7:TR?=	NYDHdGR6W0GQR1XS
OS-RC-2	M4DXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fTe2lEPTB;MUmuNVI2OiEQvF2=	NHz3c2VUSU6JRWK=
D-423MG	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\odXVKSzVyPUG5MlM6PTJizszN	MlflV2FPT0WU
LC-2-ad	NXrXbXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\6V2lEPTB;MUmuO\|YyOiEQvF2=	MnHiV2FPT0WU
DU-4475	NVnXbYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTF7Lki4OVIh\|ryP	NFvGOZBUSU6JRWK=
YKG-1	NW[3Z2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTF7Lkm2NkDPxE1?	MnniV2FPT0WU
HCC1569	NGTSPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\uPZVKSzVyPUKwMlI3OjRizszN	NYPBRol1W0GQR1XS
TYK-nu	M4XxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTpTWM2OD1{MD6yPFQ4KM7:TR?=	MnW5V2FPT0WU
DEL	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v4e2lEPTB;MkCuPVgxQCEQvF2=	MoLxV2FPT0WU
MHH-ES-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJzLkO1PVch\|ryP	NIPUVplUSU6JRWK=
KARPAS-299	M4O0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHz5VHZKSzVyPUKxMlUzQSEQvF2=	NWm4OmRDW0GQR1XS
CTV-1	M1\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvvcHR1UUN3ME2yNU43OTd{IN88US=>	NFm0N2ZUSU6JRWK=
NCI-H2452	NXywdmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoW2TWM2OD1{Mj62Olc4KM7:TR?=	M2T1OXNCVkeHUh?=
D-566MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L3WGlEPTB;MkKuO\|YxOSEQvF2=	Mk\5V2FPT0WU
EFO-27	M1XEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PoOmlEPTB;MkOuNFY2OSEQvF2=	MV\TRW5ITVJ?
NCI-H596	M1PVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkG3TWM2OD1{Mz64OVI4KM7:TR?=	NXqyUplUW0GQR1XS
KS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXkTWM2OD1{ND6yO\|U6KM7:TR?=	MoXFV2FPT0WU
8305C	NEXXWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rLVmlEPTB;MkSuOFA1PSEQvF2=	MmHyV2FPT0WU
A427	NF25TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTXeGpKSzVyPUK1MlA{OjNizszN	MYnTRW5ITVJ?
COLO-800	NVnST4R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzUTlhoUUN3ME2yOU4yODZzIN88US=>	NGHQR5BUSU6JRWK=
SJRH30	NHvUcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TTe2lEPTB;MkWuN\|kxQCEQvF2=	NIS5fGlUSU6JRWK=
MEL-HO	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PxWGlEPTB;MkWuOFMyQSEQvF2=	MXHTRW5ITVJ?
FTC-133	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml34TWM2OD1{NT64NVg3KM7:TR?=	MXvTRW5ITVJ?
SF295	NX[xVno4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\LZW05UUN3ME2yOk4zQTZizszN	NGnx[41USU6JRWK=
SW1710	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFL1ZWlKSzVyPUK2MlQyOjNizszN	MYLTRW5ITVJ?
EFM-19	MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PmemlEPTB;Mk[uPFE1PSEQvF2=	MUnTRW5ITVJ?
NB10	NFTiOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrxVIZXUUN3ME2yPE4zOjl5IN88US=>	M1\pb3NCVkeHUh?=
TK10	NHjGWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XS[mlEPTB;MkiuNlM6QSEQvF2=	M4TLe3NCVkeHUh?=
D-502MG	NF7OcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLISWJKSzVyPUK4MlQh\|ryP	MkTyV2FPT0WU
EW-18	NYn5cpA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTJ6LkSzPFYh\|ryP	MUDTRW5ITVJ?
VMRC-RCZ	M13rUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfQTWM2OD1{OD65OFEh\|ryP	NIf5TIdUSU6JRWK=
Ca9-22	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz5eZFtUUN3ME2yPU41PTV5IN88US=>	NHH0V4hUSU6JRWK=
KYSE-70	MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTteIJrUUN3ME2yPU42Pzh4IN88US=>	NX64O\|E3W0GQR1XS
A101D	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTJ7Lk[0O\|Ih\|ryP	M{jnWXNCVkeHUh?=
WM-115	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJ7Lke2NFch\|ryP	NGfmSJVUSU6JRWK=
HCC2157	NGr5VWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\sNopyUUN3ME2yPU45QDB5IN88US=>	MVPTRW5ITVJ?
TE-9	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPGTWM2OD1{OT64PFY2KM7:TR?=	NHfNcGlUSU6JRWK=
K-562	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLjTWM2OD1\|MD6wPVM{KM7:TR?=	NG\ROGhUSU6JRWK=
SN12C	M4jWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvQTWM2OD1\|MD6xOFI3KM7:TR?=	MoOzV2FPT0WU
ESS-1	M2LpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPpWlh3UUN3ME2zNE41PzV7IN88US=>	NH34OodUSU6JRWK=
K5	NEnxbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTNyLke2OEDPxE1?	Mk\6V2FPT0WU
J82	NHjjN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XUUmlEPTB;M{GuNFg6PyEQvF2=	NWnRZ4hEW0GQR1XS
HOP-92	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnEU4VWUUN3ME2zNU4yOTFzIN88US=>	MlXqV2FPT0WU
NCI-H2228	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrETWM2OD1\|MT6zNlk3KM7:TR?=	NEH2T5NUSU6JRWK=
OCI-AML2	NVvhV\|BrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHmVW9KSzVyPUOxMlM3OSEQvF2=	NF75dVBUSU6JRWK=
NCI-SNU-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn2UYRLUUN3ME2zNU45OTN5IN88US=>	MYLTRW5ITVJ?
A3-KAW	M4TwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUS2RWNCUUN3ME2zNU46OjR\|IN88US=>	NWjpOldwW0GQR1XS
LCLC-103H	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnkRmhFUUN3ME2zNk4xOTdzIN88US=>	MX7TRW5ITVJ?
KY821	NHPQOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTN{Lk[4PFQh\|ryP	MVfTRW5ITVJ?
JVM-2	NUnWc5I2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTSN2VKSzVyPUOyMlkxPzlizszN	M3zsNXNCVkeHUh?=
Mo-T	M4HONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmm5TWM2OD1\|Mz6xNFA2KM7:TR?=	M2fBTHNCVkeHUh?=
IA-LM	M3TBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3nXmVKSzVyPUOzMlI4PSEQvF2=	NYPxWmlHW0GQR1XS
C8166	NF2xVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TBZWlEPTB;M{OuN\|E6OiEQvF2=	M2\IO3NCVkeHUh?=
TCCSUP	NV3veYVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDWTWM2OD1\|Mz60N\|A4KM7:TR?=	Mm\RV2FPT0WU
JEG-3	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLVTWM2OD1\|Mz60O\|Y5KM7:TR?=	M1XVWHNCVkeHUh?=
MS-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjFe\|V6UUN3ME2zN{42PTVzIN88US=>	NHG0NGhUSU6JRWK=
NCI-H1304	NYfze3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\wSWlEPTB;M{OuOVczPSEQvF2=	NIPLNmxUSU6JRWK=
Ramos-2G6-4C10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LNVWlEPTB;M{SuNFM{PSEQvF2=	NXXTWnN3W0GQR1XS
MDA-MB-453	NEjKd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDnUFNKSzVyPUO0MlY{QTVizszN	NHL5UXJUSU6JRWK=
KYSE-520	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PpR2lEPTB;M{SuO\|E5OSEQvF2=	MYXTRW5ITVJ?
SW900	NGnteZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrVOGt[UUN3ME2zOE45OTF3IN88US=>	NF36NotUSU6JRWK=
HCC2998	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi1W5FKSzVyPUO1MlE2OjlizszN	NY[2NVYyW0GQR1XS
A2058	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTN3Lk[wOlEh\|ryP	M{LUPXNCVkeHUh?=
OVCAR-3	M4jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTN4LkKwOFUh\|ryP	MnXXV2FPT0WU
MOLT-4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTN4LkKyPVQh\|ryP	MkTQV2FPT0WU
CAPAN-1	M2fVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rUbWlEPTB;M{[uOFY6QSEQvF2=	MUTTRW5ITVJ?
SCC-9	M{LVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTN5LkSwNlch\|ryP	M4CwVXNCVkeHUh?=
SF268	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17nVWlEPTB;M{iuN\|Q{OyEQvF2=	NULaco8yW0GQR1XS
HGC-27	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTN6LkO3NVEh\|ryP	NX;HT5N2W0GQR1XS
DOHH-2	NEXTeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmO0TWM2OD1\|OD63NVU5KM7:TR?=	NFL2T2JUSU6JRWK=
KE-37	M{jjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjqfFFZUUN3ME2zPE46QDJ6IN88US=>	M1vMd3NCVkeHUh?=
MOLT-13	M1zkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTJdYFQUUN3ME2zPU4zPTB{IN88US=>	MmL2V2FPT0WU
ES1	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3y0TWlEPTB;M{muN\|g2KM7:TR?=	NGH6PZBUSU6JRWK=
SK-OV-3	NUHyPVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTN7Lkm2OFMh\|ryP	NXzh[I1EW0GQR1XS
SNU-449	NF[wZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnCTWM2OD12MD6wO\|Y1KM7:TR?=	MVfTRW5ITVJ?
KYSE-510	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVK1OmZUUUN3ME20NE4yOjl3IN88US=>	M1nFd3NCVkeHUh?=
HL-60	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPlTGhSUUN3ME20NE46Pzh\|IN88US=>	NH24cplUSU6JRWK=
DJM-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnaWW5KSzVyPUSwMlk4QTlizszN	MYnTRW5ITVJ?
TGBC11TKB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXruUlhsUUN3ME20NU4xQTJ4IN88US=>	NXr4c3VvW0GQR1XS
U-2-OS	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37JfGlEPTB;NEKuNlY1OSEQvF2=	NE\0SWVUSU6JRWK=
NCI-H2030	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojvTWM2OD12Mj60N\|Y5KM7:TR?=	M{TMSXNCVkeHUh?=
LU-135	NXnhWG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LwRWlEPTB;NEKuOVQ1PyEQvF2=	MojOV2FPT0WU
ZR-75-30	NWnoWm17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nrN2lEPTB;NEOuNFQ6OyEQvF2=	M1y4b3NCVkeHUh?=
GT3TKB	M4PoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;YTWM2OD12Mz6yOlc6KM7:TR?=	NEHwbWtUSU6JRWK=
RPMI-2650	NHTwOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTR\|Lke4NVYh\|ryP	NV\4TnAyW0GQR1XS
SAS	M13j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDvSpBGUUN3ME20N{46PTN2IN88US=>	NFvybJlUSU6JRWK=
MDA-MB-231	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPMTWM2OD12Mz65OlA6KM7:TR?=	NVfvWoJwW0GQR1XS
JVM-3	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn2eHc3UUN3ME20OE4xPTN\|IN88US=>	M37YTHNCVkeHUh?=
COLO-320-HSR	NHPRZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTR2LkW2N\|Mh\|ryP	MVrTRW5ITVJ?
SNB75	M{LTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LSWWlEPTB;NESuOlExPSEQvF2=	NWnmUZdjW0GQR1XS
NCI-H441	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT0fIdKSzVyPUS0Mlk{OjhizszN	MlHHV2FPT0WU
HCT-116	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjFTWM2OD12ND65PFY5KM7:TR?=	MlXqV2FPT0WU
NCI-H226	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfqTWM2OD12NT62N\|Y5KM7:TR?=	NGGwTmpUSU6JRWK=
CAL-33	MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkS2TWM2OD12NT65NlE4KM7:TR?=	MYfTRW5ITVJ?
NCI-H1437	M3PnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnIWXJKSzVyPUS2MlMzOSEQvF2=	MUDTRW5ITVJ?
HCC1187	NYnybIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHNS45KSzVyPUS2MlQzPTVizszN	M3\ofnNCVkeHUh?=
NUGC-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTR4LkW3NFkh\|ryP	NV;mXolKW0GQR1XS
T98G	NH;HboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUL4SmRHUUN3ME20O{42PDdizszN	MV3TRW5ITVJ?
OVCAR-8	M1u4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH1WHpKSzVyPUS3MlY5OyEQvF2=	NUe0SIlQW0GQR1XS
LB2241-RCC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjyNphQUUN3ME20O{44OjdizszN	MXzTRW5ITVJ?
NCI-H358	M17IRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGyXZFRUUN3ME20PE4yOTV{IN88US=>	M{nDW3NCVkeHUh?=
PANC-08-13	NH3VWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfzRmNtUUN3ME20PE4yQDV\|IN88US=>	NFnzeXVUSU6JRWK=
KP-N-YN	NYPNWmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TjdWlEPTB;NEiuNlExOiEQvF2=	NVi2UIRyW0GQR1XS
NCI-H1755	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7oOmFDUUN3ME20PE4zPzJ4IN88US=>	M2jt[nNCVkeHUh?=
NCI-N87	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGSwRWpKSzVyPUS4MlI6QTFizszN	Mmr3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFGFR2 / FGFR2 ; PubMed: 24968263 PLoS One PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody. p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; PubMed: 24968263 PLoS One Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.	24968263
Growth inhibition assay	Cell viability; PubMed: 24968263 PLoS One B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism.	24968263

体内研究

PD173074在1 mg/kg/day或2 mg/ka/day对小鼠给药可以剂量依赖性的方式有效阻止由FGF或VEGF诱导的血管生成，并没有明显的毒性。^[1] PD173074抑制FGFR3突变体转染的NIH 3T3细胞在裸鼠体内生长。在KMS11异种移植瘤模型中，PD173074抑制FGFR3导致肿瘤生长延缓，小鼠的存活率提高。^[4] 在H-510异种移植体中，PD173074阻断肿瘤生长和cisplatin相似，与对照假治疗的动物相比增加中位生存期。在H-69异种移植体中，PD173074在50％小鼠中的诱导作用长于6个月。这些效应是和切除肿瘤中增加的细胞凋亡相关的，而非破坏肿瘤血管。^[5]

激酶实验：^[1]	- 合并体外激酶抑制试验: 检测是使用全长FGFR-1激酶在100微升含25 mM HEPES缓冲液（pH7.4），150 mM氯化钠，10 mM MnCl_{2，0.2 mM的原钒酸钠，750 μg/mL谷氨酸和酪氨酸（4:1）的无规共聚物，各种浓度的PD173074，和60至75 ng酶中进行的。该反应通过加入[γ-³²P]ATP（含有0.4 μCi of [γ-³²P]ATP的5 μM ATP）起始，样品在25°C孵育10分钟。反应通过加入30％三氯乙酸和材料的沉淀到玻璃纤维滤垫上终止。过滤器用15％三氯乙酸洗涤三次，掺入[³²P]到谷氨酸酪氨酸聚合物衬底是通过计算保留在过滤器上的放射性来确定，通过WALLAC1250 betaplate阅读器读取。非特异性的活性被定义为温育不含酶的样品保留在过滤器上放射性。特异活性被确定为总活性（酶加缓冲液）减去非特异性活性。PD173074抑制FGFR-1的酶活性的IC50浓度用图解法测定。}
细胞实验：^[4]	- 合并 Cell lines: KMS11和 KMS18 Concentrations: 溶解在DMSO中至终浓度~100 nM Incubation Time: 48小时 Method: 在aFGF/肝素的存在下，细胞在PD173074浓度梯度中孵育48小时。活细胞的百分比由MTT法检测。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 诱导角膜新生血管的瑞士韦伯斯特小鼠 Dosages: 约2 mg/kg/day Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PD173074 SDF

分子量	523.67
化学式	C₂₈H₄₁N₇O₃
CAS号	219580-11-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the half-life of PD173074(S1264) in vivo?
回答：
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

泛FGFR抑制剂

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
活性最高的FGFR抑制剂

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA批准的FGFR抑制剂

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
最新的FGFR抑制剂

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

研究领域

产品类型

定制您的化合物库

PD173074

客户使用Selleck生产的PD173074发表文献81篇：

产品安全说明书

FGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PD173074 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品